Medscape Medical News, October 22, 2015. In approving new cancer drugs, the US Food and Drug Administration (FDA) is now heavily relying on surrogate markers of effectiveness, such as tumor shrinkage, instead of proof that an agent improves survival, according to a new analysis.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
How Fast to “Cures” and at What Cost? Politico Forum Tilts Toward Pharma-Friendly Messaging
Health News Review, October 20, 2015. At an event entitled “How Fast to Cures?” hosted by Politico, the topic of discussion by four professionals from various realms of the research and health care advocacy world was the increasingly contentious 21st Century Cures Act.
Read More »Theranos Limits Use of Blood Test Technology
Medscape Medical News, October 16, 2015. Theranos, the clinical lab company revolutionizing its industry with low-cost finger-prick tests, is limiting the use of its tiny blood vials to assays approved by the US Food and Drug Administration (FDA), company CEO Elizabeth Holmes said yesterday.
Read More »Would Washington’s FDA Fix Cure the Patients or the Drug Industry?
ProPublica, October 20, 2015. In Congress, however, things are looking better for the manufacturers. Legislation is advancing that would speed up the FDA’s approval process for medications and medical devices, offering a rare example of how major initiatives can get traction even in today’s gridlocked Washington.
Read More »Bernie Sanders Opposes Califf for FDA Post Cites Industry Ties
Mad in America, October 16, 2015. Current presidential hopeful and longtime Vermont independent senator, Bernie Sanders, said that he will vote against Robert Califf’s nomination to lead the Food and Drug Administration (FDA). Sanders explained his opposition by citing Califf’s extensive ties to the pharmaceutical companies that he would be in charge of regulating.
Read More »